AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20435991 — intervention group
Group type: EXPERIMENTAL
Intervention: small-molecule glycoprotein IIb/IIIa inhibitors (smGPIs)
Number of subjects: 2040
Study 20435991 — intervention group
Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 2040
Study 18687841 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-based solution preparation for 90 seconds
Number of subjects: 0
Study 18687841 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear fluid antiseptic preparation for 60 seconds
Number of subjects: 0
Study 18687841 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear fluid antiseptic preparation for 90 seconds
Number of subjects: 0
Study 18687841 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-based solution preparation for 60 seconds
Number of subjects: 0
Study 16850654 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program and problem solving work group
Number of subjects: 24
Study 16850654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 12783111 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 2g/day plus vitamin E 400 IU/day (group B)
Number of subjects: 41
Study 12783111 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 2g/day plus vitamin E 800 IU/day (group C)
Number of subjects: 41
Study 12783111 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 2g/day (group A)
Number of subjects: 41
Study 12783111 — intervention group
Group type: COMPARATOR
Intervention: No antioxidants (controls, group D)
Number of subjects: 41
Study 11039375 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid conduit
Number of subjects: 98
Study 11039375 — intervention group
Group type: COMPARATOR
Intervention: Standard repair (end-to-end or nerve graft)
Number of subjects: 98
Study 11039375 — intervention group
Group type: COMPARATOR
Intervention: Nerve graft
Number of subjects: 98
Study 8853850 — intervention group
Group type: EXPERIMENTAL
Intervention: White males
Number of subjects: 64
Study 8853850 — intervention group
Group type: COMPARATOR
Intervention: Black males
Number of subjects: 64
Study 8853850 — intervention group
Group type: EXPERIMENTAL
Intervention: White females
Number of subjects: 64
Study 8853850 — intervention group
Group type: COMPARATOR
Intervention: Black females
Number of subjects: 64
Study 1500891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 19
Study 1500891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6425231 — intervention group
Group type: EXPERIMENTAL
Intervention: GP 53.633 (GP)
Number of subjects: 24
Study 6425231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30454876 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent support
Number of subjects: 56
Study 30454876 — intervention group
Group type: COMPARATOR
Intervention: No support
Number of subjects: 56
Study 29869004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular supplementation of vitamin D with a single dose of 600,000 IU cholecalciferol
Number of subjects: 20
Study 29869004 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral supplementation limited to 1400 IU of vitamin D)
Number of subjects: 20
Study 27160498 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nutritional therapy (oral, enteral, and parenteral)
Number of subjects: 0
Study 27160498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional strategy based on disease-specific guidelines
Number of subjects: 0
Study 25494823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin A (CsA) monitored by residual NFAT-regulated gene expression
Number of subjects: 0
Study 25494823 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin A (CsA) monitored by trough levels
Number of subjects: 0
Study 22167539 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 266
Study 22167539 — intervention group
Group type: COMPARATOR
Intervention: Xalatan® (latanoprost 0.005%)
Number of subjects: 266
Study 22167539 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% and Xalatan®
Number of subjects: 266
Study 21117407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg ACTH stimulation test
Number of subjects: 10
Study 21117407 — intervention group
Group type: COMPARATOR
Intervention: 250 microg ACTH stimulation test
Number of subjects: 10
Study 21117407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests (1 microg and 250 microg ACTH)
Number of subjects: 10
Study 17435458 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFAs alone
Number of subjects: 132
Study 17435458 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFAs + micronutrients
Number of subjects: 132
Study 17435458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 10953902 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day for 5 days to 3 g/day for 9 weeks)
Number of subjects: 48
Study 9105072 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (up to four doses of 100 mg phospholipids/kg)
Number of subjects: 59
Study 9105072 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy only)
Number of subjects: 59
Study 1337163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium PD fluid (calcium 1.25 mmol/l) with oral calcium carbonate
Number of subjects: 50
Study 1337163 — intervention group
Group type: COMPARATOR
Intervention: Standard PD solution (calcium 1.75 mmol/l) with calcium carbonate plus aluminium hydroxide phosphate binders
Number of subjects: 50
Study 1337163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium PD fluid (calcium 1.25 mmol/l)
Number of subjects: 50
Study 1337163 — intervention group
Group type: COMPARATOR
Intervention: Standard PD solution (calcium 1.75 mmol/l)
Number of subjects: 50
Study 2435043 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenoxybenzamine (10 mg b.i.d.; n = 21)
Number of subjects: 43
Study 2435043 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (n = 22)
Number of subjects: 43
Study 29634086 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel cardiovascular disease prevention program (6 months, twice-weekly exercise, nutrition, and heart health classes)
Number of subjects: 194
Study 29634086 — intervention group
Group type: COMPARATOR
Intervention: Education-only control program (didactic healthy lifestyle classes once a month for 6 months)
Number of subjects: 194
Study 27792801 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacrylate-based composite resin (Filtek Z250)
Number of subjects: 31
Study 27792801 — intervention group
Group type: EXPERIMENTAL
Intervention: Silorane-based composite resin (Silorane P90)
Number of subjects: 31
Study 27792801 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacrylate-based composite resin (Filtek Z250) with oxalic acid-based desensitizing agent (Desenssiv, SSWhite)
Number of subjects: 31
Study 27792801 — intervention group
Group type: EXPERIMENTAL
Intervention: Silorane-based composite resin (Silorane P90) with oxalic acid-based desensitizing agent (Desenssiv, SSWhite)
Number of subjects: 31
Study 24826855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic ultrasound simulators (PS)
Number of subjects: 134
Study 24826855 — intervention group
Group type: COMPARATOR
Intervention: Live models (LM)
Number of subjects: 134
Study 22713543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency γ-oscillations originating in fronto-parietal networks
Number of subjects: 0
Study 22713543 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional networks
Number of subjects: 0
Study 20067954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) alone
Number of subjects: 126
Study 20067954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus daclizumab (DZB)
Number of subjects: 126
Study 20067954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 18472355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 221
Study 18472355 — intervention group
Group type: COMPARATOR
Intervention: Conventional Radiotherapy (CRT)
Number of subjects: 221
Study 15696400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (1.5 mg/kg)
Number of subjects: 12
Study 15696400 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg)
Number of subjects: 12
Study 12889588 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment for trichomoniasis
Number of subjects: 2
Study 12889588 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment for bacterial vaginosis
Number of subjects: 2
Study 12889588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 10574370 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microM roscovitine
Number of subjects: 8
Study 10574370 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 8
Study 9592308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulperazone (SPZ)
Number of subjects: 73
Study 9592308 — intervention group
Group type: COMPARATOR
Intervention: Tienam (TIM)
Number of subjects: 73
Study 2048463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizes Anorectic Cognitions (MAC) questionnaire
Number of subjects: 100
Study 31781880 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied coenzyme Q10 (CoQ10)
Number of subjects: 93
Study 31781880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 93
Study 31512143 — intervention group
Group type: EXPERIMENTAL
Intervention: TurboCBD™ 90 mg
Number of subjects: 12
Study 31512143 — intervention group
Group type: COMPARATOR
Intervention: 90 mg control
Number of subjects: 12
Study 31512143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28223262 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message intervention
Number of subjects: 1139
Study 28223262 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient survey (paper or telephone interview)
Number of subjects: 1139
Study 28223262 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors
Number of subjects: 1139
Study 25579777 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccine (PPV23)
Number of subjects: 152723
Study 25579777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152723
Study 23662815 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 28
Study 23662815 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational incentives (reward, response cost)
Number of subjects: 28
Study 23662815 — intervention group
Group type: COMPARATOR
Intervention: Baseline (low incentive)
Number of subjects: 28
Study 23662815 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 28
Study 21899812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy using liquid nitrogen
Number of subjects: 240
Study 21899812 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid (50% self-treatment)
Number of subjects: 240
Study 21899812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 240
Study 21899812 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid
Number of subjects: 240
Study 19473560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injection with triamcinolone hexacetonide 60 mg and xylocaine chloride 2% (IAI group)
Number of subjects: 60
Study 19473560 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of triamcinolone acetonide 60 mg and xylocaine chloride 2% (IM group)
Number of subjects: 60
Study 17636114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower third of the change in moderate-to-vigorous physical activity (PA)
Number of subjects: 479
Study 17636114 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper third of the change in moderate-to-vigorous physical activity (PA)
Number of subjects: 479
Study 17636114 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare allele carriers of SNPs
Number of subjects: 479
Study 16299426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders (panic disorder, posttraumatic stress disorder, social phobia)
Number of subjects: 480
Study 16299426 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 480
Study 16299426 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized anxiety disorder
Number of subjects: 480
Study 16299426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders overall
Number of subjects: 480
Study 16299426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders (combined with chronic physical illness, major depression, and socioeconomic factors)
Number of subjects: 480
Study 12374678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alpha-difluoromethylornithine (DFMO) 0.5 g/m(2)/day for 6 months
Number of subjects: 119
Study 12374678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 10075594 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 348
Study 7478691 — intervention group
Group type: EXPERIMENTAL
Intervention: Real heelstick condition
Number of subjects: 48
Study 7478691 — intervention group
Group type: COMPARATOR
Intervention: Sham heelstick condition
Number of subjects: 48
Study 2154068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin infusions (500 mg/kg x 3 doses, followed by 250 mg/kg x 2 doses at 2-week intervals)
Number of subjects: 34
Study 2154068 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 34
Study 7276205 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 7276205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0
Study 7276205 — intervention group
Group type: EXPERIMENTAL
Intervention: Distalgesic (paracetamol and dextropropoxyphene)
Number of subjects: 0
Study 30951917 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 314
Study 30951917 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 314
Study 30951917 — intervention group
Group type: COMPARATOR
Intervention: Both CEA and CAS
Number of subjects: 314
Study 28884989 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg daily for 12 weeks
Number of subjects: 60
Study 28884989 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 28884989 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 60
Study 28884989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28884989 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label HCQ
Number of subjects: 60
Study 28884989 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonist (LTRA)
Number of subjects: 60
Study 28884989 — intervention group
Group type: COMPARATOR
Intervention: LTRA
Number of subjects: 60
Study 25872950 — intervention group
Group type: EXPERIMENTAL
Intervention: Five weekly psychosocial interventions based on cognitive behavioral therapy (CBT) in combination with early palliative care (PC)
Number of subjects: 0
Study 25872950 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (PC) only
Number of subjects: 0
Study 25872950 — intervention group
Group type: COMPARATOR
Intervention: Standard oncologic care
Number of subjects: 0
Study 24064164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing material 1
Number of subjects: 63
Study 24064164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing material 2
Number of subjects: 63
Study 24064164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing material 3
Number of subjects: 63
Study 24064164 — intervention group
Group type: COMPARATOR
Intervention: Positive control (Group 4)
Number of subjects: 63
Study 24064164 — intervention group
Group type: COMPARATOR
Intervention: Negative control (Group 5)
Number of subjects: 63
Study 21352559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative local anaesthetic wound infiltration (60 mls of 0.25% bupivacaine with 1 in 200,000 adrenaline)
Number of subjects: 600
Study 21352559 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 600
Study 21352559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative local anaesthetic wound infiltration
Number of subjects: 600
Study 19763132 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan/hydrochlorothiazide (L/HCTZ)
Number of subjects: 30
Study 19763132 — intervention group
Group type: COMPARATOR
Intervention: losartan
Number of subjects: 30
Study 17088140 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab at 3 mg/kg
Number of subjects: 24
Study 17088140 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab at 1 mg/kg
Number of subjects: 24
Study 17088140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17088140 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab (both dosages)
Number of subjects: 24
Study 14758156 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional-assist ventilation (PAV)
Number of subjects: 7
Study 14758156 — intervention group
Group type: COMPARATOR
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 7
Study 11349183 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Number of subjects: 18
Study 11349183 — intervention group
Group type: COMPARATOR
Intervention: benzoporphyrin-derivative monoacid ring
Number of subjects: 18
Study 9154675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 60
Study 9154675 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 60
Study 9154675 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 9154675 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 60
Study 7967420 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with 2 therapy courses for completely resected patients (branch R1)
Number of subjects: 212
Study 7967420 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with 4 therapy courses for patients with extra-abdominal localization or abdominal localization and LDH < 500 U/l (branch R2)
Number of subjects: 212
Study 7967420 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with 6 therapy courses for patients with abdominal localization and LDH >= 500 U/l (branch R3)
Number of subjects: 212
Study 7967420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification therapy for patients with incomplete response after 2 courses
Number of subjects: 212
Study 7967420 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS chemotherapy for CNS positive patients
Number of subjects: 212
Study 7967420 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pEFS for stage III abdominal disease and LDH >= 500 U/l
Number of subjects: 212
Study 2889307 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (20 mg po, three times a day)
Number of subjects: 7
Study 2889307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29681624 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE+
Number of subjects: 91
Study 29681624 — intervention group
Group type: COMPARATOR
Intervention: ROSE-
Number of subjects: 91
Study 26791187 — intervention group
Group type: EXPERIMENTAL
Intervention: Average-protein diets (15% of daily energy)
Number of subjects: 1092
Study 26791187 — intervention group
Group type: COMPARATOR
Intervention: High-protein diets (25% of daily energy)
Number of subjects: 1092
Study 26791187 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 1092
Study 26791187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in alanine and AAA tyrosine
Number of subjects: 1092
Study 23116214 — intervention group
Group type: EXPERIMENTAL
Intervention: Unani formulation for ulcer healing
Number of subjects: 0
Study 22771577 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation autonomy (content viewing order dictated based on stage of change)
Number of subjects: 0
Study 22771577 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of self-efficacy based testimonials (yes)
Number of subjects: 0
Study 22771577 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive outreach (reminder emails)
Number of subjects: 0
Study 22771577 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional framework (prescriptive tone)
Number of subjects: 0
Study 22771577 — intervention group
Group type: COMPARATOR
Intervention: Navigation autonomy (content viewing order not dictated by stage of change)
Number of subjects: 0
Study 22771577 — intervention group
Group type: COMPARATOR
Intervention: Use of self-efficacy based testimonials (no)
Number of subjects: 0
Study 22771577 — intervention group
Group type: COMPARATOR
Intervention: Proactive outreach (no emails)
Number of subjects: 0
Study 22771577 — intervention group
Group type: COMPARATOR
Intervention: Decisional framework (motivational tone)
Number of subjects: 0
Study 20733102 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 611
Study 20733102 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 611
Study 20733102 — intervention group
Group type: COMPARATOR
Intervention: MT
Number of subjects: 611
Study 18608042 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at 0, 6, 12, 24, 36, 48, 72 and 96 hours following admission
Number of subjects: 455
Study 18608042 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP measurement combined with one value taken between 24 and 96 hours (at 48 hours)
Number of subjects: 455
Study 15970119 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted strategy (interactive educational meetings, local consensus process)
Number of subjects: 153
Study 15970119 — intervention group
Group type: COMPARATOR
Intervention: Passive dissemination strategy
Number of subjects: 153
Study 12358335 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (BDP) at doses of 50, 100, 200, or 500 microg x day(‐1) for eight weeks
Number of subjects: 65
Study 12358335 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (BDP)
Number of subjects: 65